omniture

Renhuang Pharmaceuticals, Inc. Co-Sponsors Sino-German Workshop on Sleep Research

2008-05-16 19:45 4076



HARBIN, China, May 16 /Xinhua-PRNewswire-FirstCall/ -- Renhuang Pharmaceuticals, Inc. (Pink Sheets: RHGP) ("Renhuang" or "the Company"), a leading pharmaceutical company in the People's Republic of China ("PRC"), today announced its participation as a co-sponsor of the first Sino-German Workshop on Sleep Research, hosted in Harbin, China, recently.

The Sino-German Workshop on Sleep Research was organized jointly by Heilongjiang University of Chinese Medicine and MPI of Psychiatry, Munich, Center of Mental Health. The workshop was sponsored by the Sino-German Center for Research Promotion and co-sponsored by Renhuang Pharmaceuticals, Inc. Professor Tingli Li of Heilongjiang University of Chinese Medicine and Mr. Shaoming Li, President and CEO of Renhuang Pharmaceuticals represented the PRC as co-chairs of the workshop.

At the workshop, over 50 scientists from China, Germany, the U.S., Holland, Austria, Russia, Japan and other countries presented their research findings on a wide variety of topics, including sleep apnea, anxiety induced sleep disorders, insomnia, and shared statistics regarding Chinese treatments for sleep disorders.

Renhuang presented the study results on its leading branded drug, Acanthopanax (Siberian Ginseng), which treats sleep disorders and depression by reducing tension and putting individuals in a more relaxed state. Since Acanthopanax was the only drug with a significant amount of research supporting its use in the treatment of sleep disorders at the workshop, it garnered a great deal of attention among the workshop attendees.

"By co-sponsoring the Sino-German Workshop on Sleep Disorders, we continued our strategy of increasing our presence at scientific workshops and increasing our communications and exchanging study results with well known researchers around the world. We plan to reach out to more professionals regarding the use of Acanthopanax in the treatment of sleep disorders, which will further expand our global reach," said Mr. Shao-ming Li, Chairman and CEO of Renhaung Pharmaceuticals, Inc.

About Renhuang Pharmaceuticals, Inc.

Founded in 1996, Renhuang Pharmaceuticals, Inc, produces western, traditional Chinese medicines (TCM), and branded pharmaceuticals, using its GMP-certified facilities in China. The Company's GMP-certified manufacturing facilities, containing cutting-edge technologies and advance equipment, are capable of producing as many as 200 types of pharmaceuticals. Additionally, Renhuang distributes raw materials and finished pharmaceutical products using its extensive distribution channels and third party distributors throughout China. The Company's distribution network includes over 3,000 sales representatives in 70 sales centers across 24 districts, covering over 50% of the greater China. The Company also exports its products to Russia and Southeast Asia. For more information, visit http://www.renhuang.com .

Safe Harbor Statement

Certain of the statements made in the press release constitute

forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding our future plans, objectives or performance. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.

For more information, please contact:

Renhuang Pharmaceuticals, Inc.

Ms. Shuang Tan, IR Contact

Tel: +86-451-5392-5461

Email: ir@renhuang.com

Mr. Crocker Coulson, President

CCG Elite Investor Relations Inc.

Tel: +1-646-213-1915 (New York)

Email: crocker.coulson@ccgir.com

Web: http://www.ccgelite.com

Source: Renhuang Pharmaceuticals, Inc.
Related Stocks:
AMEX:CBP
collection